Skip to main content
Erschienen in:

31.01.2022 | COVID-19 | Short Communication Zur Zeit gratis

The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis

verfasst von: Chia Siang Chia Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

Erschienen in: Inflammopharmacology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Meta-analyses were utilized to determine the overall effectiveness of BNT162b2 mRNA vaccine (Pfizer vaccine) against COVID-19 caused by Delta variant from large real-world studies. A systematic literature search with no language restriction was performed in electronic databases to identify eligible observational studies that reported the effectiveness of the BNT162b2 mRNA vaccine to prevent reverse transcription-polymerase chain reaction (RT-PCR) confirmed COVID-19 caused by Delta variant of SARS-CoV-2 (B.1.617.2). Random-effects meta-analysis model was used to estimate the pooled odds ratio (OR) at a 95% confidence interval, and the vaccine effectiveness was indicated as (pooled OR – 1)/OR. Seven studies were included for this meta-analysis. The meta-analysis revealed that the administration of BNT162b2 mRNA vaccine protected against RT-PCR confirmed COVID-19 caused by Delta variant ≥ 21 days after the first dose, with vaccine effectiveness of 55% (95% confidence interval 46–63%), as well as ≥ 14 days after the second dose, with vaccine effectiveness of 81% (95% confidence interval 69–88%). In conclusion, the BNT162b2 mRNA vaccine offers a substantial protection rate against RT-PCR confirmed COVID-19 caused by the Delta variant upon full vaccination, albeit with slightly reduced effectiveness relative to other strains of SARS-CoV-2.
Literatur
Zurück zum Zitat Blanquart F, Abad C, Ambroise J, Bernard M, Cosentino G, Giannoli JM, Débarre F (2021) Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. Eurosurveillance 26(37):2100824CrossRef Blanquart F, Abad C, Ambroise J, Bernard M, Cosentino G, Giannoli JM, Débarre F (2021) Characterisation of vaccine breakthrough infections of SARS-CoV-2 Delta and Alpha variants and within-host viral load dynamics in the community, France, June to July 2021. Eurosurveillance 26(37):2100824CrossRef
Zurück zum Zitat Burki TK (2021) Lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir Med 9(8):e85CrossRef Burki TK (2021) Lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir Med 9(8):e85CrossRef
Zurück zum Zitat Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K (2021) Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 viruses. J Autoimmun 124:102715CrossRef Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, Lorson CL, Byrareddy SN, Singh K (2021) Evolutionary analysis of the delta and delta plus variants of the SARS-CoV-2 viruses. J Autoimmun 124:102715CrossRef
Zurück zum Zitat Kow CS, Hasan SS (2021) Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology 29(4):1075–1090CrossRef Kow CS, Hasan SS (2021) Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology 29(4):1075–1090CrossRef
Zurück zum Zitat Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, Casado I, Portillo ME, Navascués A, Ezpeleta C, Castilla J, Working Group for the Study of COVID-19 in Navarre; Investigators, other members of the Working Group for the Study of COVID-19 in Navarre (2021) Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, april to august 2021. Euro Surveill 26:2100894PubMedCentral Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, Fernández-Huerta M, Burgui C, Casado I, Portillo ME, Navascués A, Ezpeleta C, Castilla J, Working Group for the Study of COVID-19 in Navarre; Investigators, other members of the Working Group for the Study of COVID-19 in Navarre (2021) Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, april to august 2021. Euro Surveill 26:2100894PubMedCentral
Zurück zum Zitat Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29:372 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29:372
Zurück zum Zitat Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O (2021) Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596(7871):276–280CrossRef Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O (2021) Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596(7871):276–280CrossRef
Zurück zum Zitat Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators (2021) SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397(10293):2461–2462CrossRef Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators (2021) SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397(10293):2461–2462CrossRef
Zurück zum Zitat Skowronski DM, Setayeshgar S, Febriani Y, Ouakki M, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G (2021) Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv. https://doi.org/10.1101/2021.10.26.21265397CrossRef Skowronski DM, Setayeshgar S, Febriani Y, Ouakki M, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G (2021) Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv. https://​doi.​org/​10.​1101/​2021.​10.​26.​21265397CrossRef
Zurück zum Zitat Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S, Valluri SR (2021) Six-month effectiveness of BNT162B2 MRNA COVID-19 vaccine in a large US integrated health system: a retrospective cohort study. Lancet 398(10309):1407–1416CrossRef Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S, Valluri SR (2021) Six-month effectiveness of BNT162B2 MRNA COVID-19 vaccine in a large US integrated health system: a retrospective cohort study. Lancet 398(10309):1407–1416CrossRef
Zurück zum Zitat Weinberg GA, Szilagyi PG (2010) Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201:1607–1610CrossRef Weinberg GA, Szilagyi PG (2010) Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201:1607–1610CrossRef
Metadaten
Titel
The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis
verfasst von
Chia Siang Chia Kow
Dinesh Sangarran Ramachandram
Syed Shahzad Hasan
Publikationsdatum
31.01.2022
Verlag
Springer International Publishing
Schlagwörter
COVID-19
Virologie
Erschienen in
Inflammopharmacology / Ausgabe 1/2022
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-021-00915-7